Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26311

Title: Are vaginal swabs comparable to cervical smears for human papillomavirus DNA testing?
Authors: Coorevits, Liselotte
Traen, Ans
Binge, Luc
Van Dorpe, Jo
Praet, Marleen
Boelens, Jerina
Padalko, Elizaveta
Issue Date: 2018
Abstract: Objective: Human papillomavirus (HPV) testing is widely incorporated into cervical cancer screening strategies. Current screening requires pelvic examination for cervical sampling, which may compromise participation. The acceptance could be raised by introducing testing on vaginal swabs. We explored the interchangeability of vaginal swabs and cervical smears for HPV testing, by means of a prospective study conducted in female sex workers (FSWs). Besides, we report on the occurrence of 32 different HPV genotypes in FSW with low-grade squamous intraepithelial lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL). Methods: Paired physician-collected vaginal swabs and cervical smears from 303 FSW were tested for HPV using the Abbott RealTime High-Risk HPV assay. Cervical cytology was examined on cervical smears. In case of HSIL/LSIL cytological classification (n=52), both samples were genotyped using INNO-LiPa HPV Genotyping Extra II. Results: The overall prevalence of high-risk (HR)-HPV was 51%. In FSW with HSIL/LSIL cervical cytology, the sensitivity and specificity of vaginal samples for the detection of HRHPV was 100% and 70% and for probable HR-HPV 100% and 91%. The mean number of genotypes identified in vaginal samples (mean=3.5; 95% confidence interval [CI]=2.8-4.2) was significantly higher than in cervical smear samples (mean=2.6; 95% CI=2.1-3.0) (p=0.001). The most frequently encountered HR-HPV genotypes were HPV16, 31, 51, and 52. Conclusion: As our study shows that vaginal swabs are equivalent to cervical smears for the detection of (probable) HR-HPV, vaginal swabs can be used for HPV testing in cervical cancer screening strategies. Given the acceptance of vaginal sampling, this finding offers an opportunity to boost screening coverage.
Notes: [Coorevits, Liselotte; Boelens, Jerina; Padalko, Elizaveta] Ghent Univ Hosp, Dept Lab Med, Pintelaan 185, B-9000 Ghent, Belgium. [Coorevits, Liselotte; Boelens, Jerina; Padalko, Elizaveta] Univ Ghent, Dept Clin Chem Microbiol & Immunol, Ghent, Belgium. [Traen, Ans; Binge, Luc] Pasop Vzw, Ghent, Belgium. [Van Dorpe, Jo; Praet, Marleen] Univ Ghent, Dept Pathol, Ghent, Belgium. [Van Dorpe, Jo; Praet, Marleen] Ghent Univ Hosp, Ghent, Belgium. [Padalko, Elizaveta] Hasselt Univ, Sch Life Sci, Diepenbeek, Belgium.
URI: http://hdl.handle.net/1942/26311
DOI: 10.3802/jgo.2018.29.e8
ISI #: 000416677900008
ISSN: 2005-0380
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version1.08 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.